ARKG: Revolutionary Science, Unremarkable Returns

I rate ARK Genomic Revolution ETF a HOLD with MODERATE conviction, given high valuations and moderate expected returns (~8% pretax over 12–18 months). ARKG's top holdings—10x Genomics, Twist Bioscience, and Tempus AI—drive performance but trade at expensive revenue multiples, requiring strong execution to justify current prices. While ARKG offers exposure to transformative genomics and AI-enabled drug discovery, much of the optimism is already priced in, leaving little margin for error or disappointment.

Seeking Alpha • 7 hours ago

Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)---- $ARKG #AI--Longevica forms a star SAB to turn its $13M, 16k-subject mammalian study into AI-driven drug discovery, pet health, and novel human therapies.

Business Wire • Sep 29, 2026

Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.

Benzinga • Sep 29, 2026

4 Best ETF Areas of Q3 That Are in High Momentum

Crypto, oil, rate hedges and AI-driven themes powered Q3 ETF winners. Here are the high-momentum areas investors should watch.

Zacks Investment Research • Sep 28, 2026

3 Analysts, 3 Trades to Make Today

On any given day, there's a headline, a fear, or a worry screaming for your attention. We regularly cover those headlines here, doing our best to separate the signal from the noise so you can keep moving toward your financial goals.

InvestorPlace • Sep 22, 2026

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Benzinga • Sep 1, 2026

Best-Performing ETF Areas of August

August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.

Zacks Investment Research • Sep 1, 2026

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.

Seeking Alpha • Jul 28, 2026

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.

24/7 Wall Street • Jul 21, 2026

Best ETF Areas of June

Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.

Zacks Investment Research • Jul 6, 2026